Chan Soon-Shiong Institute for Medicine | ClinicalTrials HQ

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 3	2026-07-27		NCT06745908
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer	Platinum-resistant Ovarian Cancer	Recruiting	Phase 2	2026-07-01		NCT06710288
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer	Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm	Recruiting	Phase 1 / Phase 2	2026-02-27		NCT07049055
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Genomic Instability, Head and Neck Neoplasms, Infections, Liver Neoplasms, Male Urogenital Diseases, Microsatellite Instability, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, mismatch repair cancer syndrome 1, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, polyomavirus infectious disease, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, small cell lung carcinoma, squamous cell carcinoma, stomach disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder, viral infectious disease	Active, not recruiting	Phase 2	2026-01-14		NCT03228667
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm	Active, not recruiting	Phase 2	2025-12-15		NCT04390399
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors	Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm	Active, not recruiting	Phase 1	2025-12-11		NCT04898543